BridgeBio Pharma targets three product launches, with Attruby’s FDA decision due November 27, 2026, and a key trial readout expected within 18 months.
BridgeBio Pharma (BBIO) identified November 27, 2026, as the PDUFA date for Attruby, marking a pivotal regulatory milestone for the company. CEO Neil Kumar described Q2 2026 as a turning point, emphasizing near-term value creation tied to the drug’s next phase.
The company outlined plans for three product launches, including Attruby, while anticipating data from the RECLAIM-HP trial within the next 18 months. Kumar’s remarks framed the quarter as the start of a new growth chapter for BridgeBio.
No immediate market reaction was disclosed, but the timeline and regulatory focus may influence investor sentiment as the company advances its pipeline.